2026 New Clinical Veterinary Research: High-Purity NMN Helps Stabilize Myocardial Biomarkers
In annual pet health checkups, NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a sensitive marker of myocardial stress. When its levels exceed the normal range, it usually indicates that the heart is under tensile or metabolic stress.
The main challenge is that when many dogs test positive for elevated NT-proBNP, echocardiography and electrocardiograms (ECG) show no obvious structural abnormalities. The marker has turned "yellow," but the underlying cause remains unclear—so what should be done next?
A clinical case study published in the Journal of Advanced Veterinary and Animal Research in 2026 explores a new approach from the perspective of myocardial energy metabolism: Can oral β-nicotinamide mononucleotide (NMN)—as a direct precursor to $\text{NAD}^+$—help bring abnormal biomarkers back down by improving the energy supply to myocardial cells? This may offer a noteworthy early intervention pathway for subclinical cases where "the indicator turns red, but the cause remains unknown."
6-year-old Golden Retriever (28.5 kg, Asymptomatic): Dosed at 30 mg bid (twice daily); within just 2 weeks, NT-proBNP dropped from 1871.6 pmol/L to below 500 pmol/L, returning completely to normal.
9-year-old Toy Poodle (2.8 kg): The initial dosage of 10 mg bid yielded minimal response, and the indicator continued to rise. After adjusting to 20 mg bid for 1.5 months, the levels dropped back to the safe range. However, levels rebounded immediately 10 days after discontinuation, demonstrating the need for long-term maintenance supplementation.
12-year-old Border Collie (Chronic Hip Osteoarthritis): Administered 20 mg bid for 2.5 months; NT-proBNP dropped from 1257 pmol/L to 614.3 pmol/L. Concurrently, the renal damage marker SDMA decreased, addressing systemic chronic inflammation as well.
15-year-old Samoyed (Chronic Kidney Disease): Accumulated NT-proBNP due to poor renal clearance returned to normal levels after 20 days of administration.
Core Conclusion: In asymptomatic subclinical myocardial stress or secondary cardiac pressure from kidney disease/chronic inflammation, NMN monotherapy can effectively stabilize markers, making it a primary choice for routine cardiac maintenance in senior dogs.
Regimen: NMN (20 mg per dose, twice daily) combined with conventional cardiac medications prescribed by veterinarians.
Results: NT-proBNP levels dropped significantly, and clinical signs of heart failure (coughing, fatigue) were visibly alleviated.
Important Note: Dogs already experiencing cardiac discomfort cannot rely on NMN alone; it must be combined with standard prescription cardiac medications for synergistic management.
Results: Even with NMN added to standard heart failure medications, biomarker levels continued to rise. Both dogs ultimately passed away from heart failure.
Key Warning: Once irreversible structural damage occurs, supplementing cellular energy alone cannot reverse the pathology. NMN can only serve as a secondary supportive measure and must never replace core cardiac medications.
$\text{NAD}^+$ is a coenzyme central to systemic cellular energy metabolism and an essential substrate for longevity proteins like SIRT1. When cardiomyocytes endure prolonged oxidative stress or metabolic strain, intracellular $\text{NAD}^+$ levels decline. This directly impairs mitochondrial function and prevents energy supply from meeting the heart's workload demands, ultimately triggering abnormal myocardial stretching and excessive release of NT-proBNP into the bloodstream.
The rapid increase in $\text{NAD}^+$ levels following NMN supplementation activates three key cardioprotective pathways:
Activates SIRT1 to inhibit FOXO3a-mediated pro-apoptotic signaling, directly reducing abnormal cardiomyocyte apoptosis and lowering the risk of chronic myocardial strain.
Maintains genomic stability via the PARP-$\text{NAD}^+$-SIRT axis, offsetting accumulated minor DNA damage and preventing chronic stress from evolving into irreversible cardiomyopathy over time.
Comprehensively optimizes mitochondrial energy metabolism, fundamentally improving the overall energy balance of myocardial cells.
This gentle mechanism of "supporting energy from the cellular level" reduces myocardial stretch and abnormal secretion stress without placing extra workload on the heart, ultimately reflected in the steady decline of circulating NT-proBNP levels.
NMN is best suited as a supplemental intervention option for cases where a complete diagnostic workup reveals no obvious structural heart abnormalities, but mild-to-moderate NT-proBNP elevation is present. In these cases, weight-adjusted oral dosing (10–30 mg per dose, twice daily) can be utilized for early metabolic management.
Although clinical exploration is ongoing and larger controlled studies are needed to confirm optimal dosing, long-term safety, and treatment durations, the complete clinical data from these 8 dogs provides a valuable reference direction for veterinarians and pet owners. It opens a feasible new path for the full-cycle management of chronic conditions in aging dogs.
Summary: NMN is not a "miracle cure." In the early stages before irreversible structural damage occurs, it serves as a promising adjunctive option to explore under veterinary guidance. However, for dogs with severe heart disease, standard therapeutic protocols must be strictly followed, and single supplements should never be blindly relied upon.
Reference:
Jiang Z, Mei L, Huang Z. Exploring the therapeutic potential of β-nicotinamide mononucleotide (NMN) in regulating canine NT-proBNP levels[J]. Journal of Advanced Veterinary and Animal Research, 2026, 13(1): 11-18.
The main challenge is that when many dogs test positive for elevated NT-proBNP, echocardiography and electrocardiograms (ECG) show no obvious structural abnormalities. The marker has turned "yellow," but the underlying cause remains unclear—so what should be done next?
A clinical case study published in the Journal of Advanced Veterinary and Animal Research in 2026 explores a new approach from the perspective of myocardial energy metabolism: Can oral β-nicotinamide mononucleotide (NMN)—as a direct precursor to $\text{NAD}^+$—help bring abnormal biomarkers back down by improving the energy supply to myocardial cells? This may offer a noteworthy early intervention pathway for subclinical cases where "the indicator turns red, but the cause remains unknown."
PART 01
Clinical Evaluation in 8 Dogs: Understanding the Tiers of NMN Efficacy
This study included 8 dogs of various breeds, ages, and underlying conditions with elevated NT-proBNP levels. A standardized, weight-customized oral NMN intervention (twice daily) was administered. Blood samples were rechecked every 2–3 weeks over a 3-month follow-up period. The data showed clear stratified results:
Tier 1: Optimal Efficacy | No Structural Heart Disease, Mild-to-Moderate NT-proBNP Elevation (Dogs 1, 2, 3, 4, 8)
Applicable Scenarios: Incidental elevation found during routine checkups without coughing, wheezing, or syncope; accompanied by chronic osteoarthritis, allergic dermatitis, or chronic kidney disease (CKD), but with a normal echocardiogram.6-year-old Golden Retriever (28.5 kg, Asymptomatic): Dosed at 30 mg bid (twice daily); within just 2 weeks, NT-proBNP dropped from 1871.6 pmol/L to below 500 pmol/L, returning completely to normal.
9-year-old Toy Poodle (2.8 kg): The initial dosage of 10 mg bid yielded minimal response, and the indicator continued to rise. After adjusting to 20 mg bid for 1.5 months, the levels dropped back to the safe range. However, levels rebounded immediately 10 days after discontinuation, demonstrating the need for long-term maintenance supplementation.
12-year-old Border Collie (Chronic Hip Osteoarthritis): Administered 20 mg bid for 2.5 months; NT-proBNP dropped from 1257 pmol/L to 614.3 pmol/L. Concurrently, the renal damage marker SDMA decreased, addressing systemic chronic inflammation as well.
15-year-old Samoyed (Chronic Kidney Disease): Accumulated NT-proBNP due to poor renal clearance returned to normal levels after 20 days of administration.
Core Conclusion: In asymptomatic subclinical myocardial stress or secondary cardiac pressure from kidney disease/chronic inflammation, NMN monotherapy can effectively stabilize markers, making it a primary choice for routine cardiac maintenance in senior dogs.
Tier 2: Adjunctive Enhancement | Mild Heart Failure, No Severe Structural Damage (Dog 5)
Clinical Presentation: Dogs presenting with coughing, exertional dyspnea, or occasional syncope, but echocardiography shows no left atrial enlargement or severe valvular lesions.Regimen: NMN (20 mg per dose, twice daily) combined with conventional cardiac medications prescribed by veterinarians.
Results: NT-proBNP levels dropped significantly, and clinical signs of heart failure (coughing, fatigue) were visibly alleviated.
Important Note: Dogs already experiencing cardiac discomfort cannot rely on NMN alone; it must be combined with standard prescription cardiac medications for synergistic management.
Tier 3: Limited Efficacy | Severe Degenerative Heart Disease, End-Stage Congestive Heart Failure (Dogs 6 & 7)
Clinical Presentation: Cavalier King Charles Spaniel and senior Shih Tzu diagnosed with severe valvular degeneration, pulmonary edema, and left atrial dilation, with NT-proBNP far exceeding the 1800 pmol/L threshold.Results: Even with NMN added to standard heart failure medications, biomarker levels continued to rise. Both dogs ultimately passed away from heart failure.
Key Warning: Once irreversible structural damage occurs, supplementing cellular energy alone cannot reverse the pathology. NMN can only serve as a secondary supportive measure and must never replace core cardiac medications.
PART 02
Underlying Mechanisms: How NMN "Decompresses" the Myocardium
Unlike traditional cardiac drugs that directly modify myocardial contractility, NMN's cardioprotective effects rely entirely on boosting intracellular $\text{NAD}^+$ levels, resolving myocardial stress at its metabolic root:$\text{NAD}^+$ is a coenzyme central to systemic cellular energy metabolism and an essential substrate for longevity proteins like SIRT1. When cardiomyocytes endure prolonged oxidative stress or metabolic strain, intracellular $\text{NAD}^+$ levels decline. This directly impairs mitochondrial function and prevents energy supply from meeting the heart's workload demands, ultimately triggering abnormal myocardial stretching and excessive release of NT-proBNP into the bloodstream.
The rapid increase in $\text{NAD}^+$ levels following NMN supplementation activates three key cardioprotective pathways:
Activates SIRT1 to inhibit FOXO3a-mediated pro-apoptotic signaling, directly reducing abnormal cardiomyocyte apoptosis and lowering the risk of chronic myocardial strain.
Maintains genomic stability via the PARP-$\text{NAD}^+$-SIRT axis, offsetting accumulated minor DNA damage and preventing chronic stress from evolving into irreversible cardiomyopathy over time.
Comprehensively optimizes mitochondrial energy metabolism, fundamentally improving the overall energy balance of myocardial cells.
This gentle mechanism of "supporting energy from the cellular level" reduces myocardial stretch and abnormal secretion stress without placing extra workload on the heart, ultimately reflected in the steady decline of circulating NT-proBNP levels.
PART 03
New Veterinary Insights: A Scientific Guide to Handling Elevated NT-proBNP
While this study offers a new perspective on subclinical cardiac interventions, NMN cannot replace standard diagnostic and therapeutic procedures. When elevated NT-proBNP is detected during a pet health checkup, a comprehensive workup—including echocardiography, ECG, blood pressure monitoring, and screening for comorbidities—must be performed first to rule out organic heart diseases manageable via surgery or conventional medications.NMN is best suited as a supplemental intervention option for cases where a complete diagnostic workup reveals no obvious structural heart abnormalities, but mild-to-moderate NT-proBNP elevation is present. In these cases, weight-adjusted oral dosing (10–30 mg per dose, twice daily) can be utilized for early metabolic management.
Although clinical exploration is ongoing and larger controlled studies are needed to confirm optimal dosing, long-term safety, and treatment durations, the complete clinical data from these 8 dogs provides a valuable reference direction for veterinarians and pet owners. It opens a feasible new path for the full-cycle management of chronic conditions in aging dogs.
Summary: NMN is not a "miracle cure." In the early stages before irreversible structural damage occurs, it serves as a promising adjunctive option to explore under veterinary guidance. However, for dogs with severe heart disease, standard therapeutic protocols must be strictly followed, and single supplements should never be blindly relied upon.
Reference:
Jiang Z, Mei L, Huang Z. Exploring the therapeutic potential of β-nicotinamide mononucleotide (NMN) in regulating canine NT-proBNP levels[J]. Journal of Advanced Veterinary and Animal Research, 2026, 13(1): 11-18.
